newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

  • AEON Biopharma reported positive initial comparative analytical results for ABP-450 confirming identical amino-acid sequencing & highly similar functional characteristics to BOTOX.
  • The Company received positive feedback from the FDA at a BPD Type 2a meeting establishing a clear framework for advancing the comparative analytical plan for the ABP-450 biosimilar program.
  • AEON strengthened its balance sheet through a $6 million PIPE financing & a Daewoong note exchange, reducing outstanding debt by more than 90%.
  • John Bencich was appointed as Chief Financial Officer with over 25 years of experience in capital markets & strategic leadership.
  • LC/MS analysis of over 3,400 amino acids demonstrated a 100% sequence match between ABP-450 & BOTOX across all five proteins of the 900 kDa complex.
  • Functional analyses showed initial similarity in potency, composition, & enzymatic activity consistent with the mechanism of action.
  • AEON expects to complete the majority of its analytical comparability program in 2026 & plans to request a BPD Type 2b meeting in 2026 to discuss full-label approval.
  • The Company reported cash & cash equivalents of $3.0 million as of December 31, 2025, excluding $4.2 million received from the second closing of the PIPE financing in January 2026.
  • Including recent proceeds, cash resources are expected to fund operations into the third quarter of 2026.
  • AEON reported a net loss of $39.222 million for the year ended December 31, 2025, compared to net income of $42.005 million in 2024.
  • Research & development expenses decreased to $4.094 million in 2025 from $14.181 million in 2024.
  • An abstract regarding primary structure comparability between ABP-450 & BOTOX was accepted for presentation at the 2026 AAN Annual Meeting in Chicago.
  • ABP-450 is manufactured by Daewoong Pharmaceutical in a facility authorized by the FDA, Health Canada, & the EMA for botulinum toxin products.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, & certain other territories.